Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Motor Neuron Disease, Amyotrophic Lateral Sclerosis Clear all
Not listed No phase listed Observational

Accurate Test of Limb Isometric Strength (ATLIS) in ALS

NCT02374606
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 1Phase 2 Interventional

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

NCT05189106
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Baricitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Not yet recruiting Not applicable Interventional

iBCI Optimization for Veterans With Paralysis

NCT05470478
View directory record Official record
Conditions
Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophy
Interventions
Mobile neural decoding platform (mobile iBCI)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 1 Interventional

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

NCT00875446
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PLACEBO, GSK1223249
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Not applicable Interventional

Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers

NCT04719403
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
HealthPAL
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

NCT02794857
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jun 10, 2026, 8:25 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Research in ALS Study

NCT00136500
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2037
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Not yet recruiting Not applicable Interventional

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

NCT07454733
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Video recording, Notes Instruction
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jun 10, 2026, 8:25 AM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

NCT07259980
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Early Phase 1 Interventional

Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)

NCT02710162
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Micro Mouth Pressure Meter, Iowa Oral Performance Instrument, Electrical Impedance Myography, Capsaicin, Videofluoroscopic Swallowing Study, Pulmonary Function Testing, Swallowing Related Quality of Life Questionnaire, Functional Oral Intake Scale, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Eating Assessment Tool-10, Communicative Effectiveness Survey, The Center for Neurologic Studies Bulbar Function Scale
Device · Drug · Procedure + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2 Interventional Results available

The Effect of RNS60 on ALS Biomarkers

NCT03456882
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
RNS60
Drug
Lead sponsor
Mario Negri Institute for Pharmacological Research
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jun 10, 2026, 8:25 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

NCT05442775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jun 10, 2026, 8:25 AM EDT
Terminated No phase listed Observational

Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology

NCT00718107
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Jun 10, 2026, 8:25 AM EDT
Recruiting Early Phase 1 Interventional

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

NCT06656702
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2 Interventional

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

NCT00070993
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine monohydrate
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Jun 10, 2026, 8:25 AM EDT
Recruiting No phase listed Observational

The National Amyotrophic Lateral Sclerosis Registry

NCT01772602
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2040
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2 Interventional

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis

NCT00005766
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Creatinine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 8:25 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jun 10, 2026, 8:25 AM EDT
Not yet recruiting Phase 1 Interventional

A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

NCT07589764
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
β-hydroxy-β-methylbutyrate (HMB)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 8:25 AM EDT
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)

NCT01849770
View directory record Official record
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • Iowa City, Iowa • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jun 10, 2026, 8:25 AM EDT